ADO and neoplasm: Through animal and cell experiments, we found that NE can affect the secretion of the chemokine CXCL9 and the immunosuppressive metabolite ADO in tumour cells by regulating the WNT7A/β-catenin signalling pathway, thereby inhibiting chemotaxis and function of CD8+ T cells.